Terawulf Inc. (WULF) stock recently hit a 52-week high of $25.78, marking a 542.13% surge over the past year. Despite this strong performance, InvestingPro data suggests the stock is overvalued and the company is quickly burning through cash, even with 27.3% revenue growth. The company reported a significant earnings miss in Q1 2026 but recently acquired a hyperscale high-performance computing development site in Eastern Kentucky to expand its infrastructure.

TeraWulf's shares surged over 12% following its acquisition of the "Muskie Data Campus" in Kentucky, an AI and HPC-focused site capable of supporting 1 GW. This move expands the company's AI footprint in the state, with CEO Paul Prager emphasizing that power infrastructure and transmission access are now critical constraints in the AI market. The acquisition has generated bullish sentiment among retail traders, who are praising TeraWulf's execution compared to competitors.

TeraWulf (NASDAQ: WULF) shares surged over 13% after the company announced the acquisition of the 1 GW Muskie Data Campus in Kentucky, intended for hyperscale AI and HPC infrastructure. This new site, alongside their existing 480 MW Justified Data campus, solidifies TeraWulf's strategy of securing power-advantaged locations for next-generation computing workloads. The company expects the initial 500 megawatts to ramp up by late 2028, with an additional 500 megawatts by late 2030.

Costco (COST) stock recently pulled back 4.5% ahead of its Q3 fiscal 2026 earnings report, scheduled for May 28, with investors de-risking from the premium-valued stock. Despite positive April sales data and a dividend increase, the company faces modest legal challenges and its valuation model suggests limited upside at its current price. Key catalysts for future performance include membership renewal rates, same-warehouse sales, international expansion, and potential capital returns.

J.B. Hunt Transport Services Inc. EVP Spencer Frazier sold 2,000 shares of the company's common stock for over $516,000 on May 19, 2026. The sale occurred while the stock was near its 52-week high, reflecting a significant return over the past year. Despite the sale, Frazier retains a substantial number of direct and indirect shares, though an InvestingPro analysis suggests the stock might be overvalued.

State Street (NYSE:STT) recently hit a new 52-week high of $157.16, experiencing strong momentum with a 1.5% rise. Analysts have largely maintained a positive outlook, with a consensus "Moderate Buy" rating and a target price of $158.57, following the company's better-than-expected earnings and a declared quarterly dividend of $0.84 per share. Insider selling by executives has occurred, but institutional investors hold a significant 87.44% of the company's stock.

KLA (NASDAQ:KLAC) shares recently reached a new 52-week high, trading as high as $1,950, following strong quarterly results that surpassed EPS and revenue estimates. The company also announced a dividend increase, a 10-for-1 stock split effective June 12th, and a $7 billion share buyback program. Analysts maintain a "Moderate Buy" consensus rating for KLA, with several firms raising price targets, though some advise caution as the stock's valuation metrics are elevated.

KLA Corp (KLAC) stock rose by 5.54% on May 26, fueled by optimistic commentary from its CFO regarding the semiconductor equipment market's momentum and strong Q3 2026 results. The company anticipates wafer fab equipment spending to exceed $140 billion and announced a 10-for-1 stock split, increased dividend, and a $7 billion share buyback program. Despite some valuation concerns, KLA's crucial role in the AI-driven semiconductor boom and positive analyst sentiment are contributing to its upward movement.

Pfizer Canada announced that BRAFTOVI® (encorafenib) will be funded under Ontario's FAST program, making it the first Pfizer therapy to receive priority access for metastatic colorectal cancer with a BRAF V600E mutation. This initiative aims to accelerate access to innovative cancer treatments in Canada, addressing the significant health challenge posed by colorectal cancer and long wait times for oncology drugs. The program is seen as a key example of collaboration among industry, government, and healthcare stakeholders to improve patient outcomes.

Labcorp (LH) recently launched MyLabcorp, an AI-powered, HIPAA-compliant mobile app that integrates lab results with AI-driven explanations and services, alongside an expanded Epic Aura integration for easier test menu access. While these moves support digital healthcare expansion and volume growth, the core investment narrative for Labcorp remains tied to managing reimbursement risks like PAMA and competitive pressures. The company's forecast projects significant revenue and earnings by 2029, suggesting a potential upside for shareholders despite these challenges.